Keytruda, Merck and Colorectal Cancer
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. Th
GlobalData on MSN3d
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.
STAT4d
The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions
Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...
BioSpace11d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
STAT12d
FDA formalizes protocol for international cancer trials
The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...
Cure Today9d
Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...
STAT4d
The science behind Summit’s success, 23andMe’s fate, and more biotech news updates
Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.
Cure Today12d
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...